ZA201801656B - Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy - Google Patents

Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Info

Publication number
ZA201801656B
ZA201801656B ZA2018/01656A ZA201801656A ZA201801656B ZA 201801656 B ZA201801656 B ZA 201801656B ZA 2018/01656 A ZA2018/01656 A ZA 2018/01656A ZA 201801656 A ZA201801656 A ZA 201801656A ZA 201801656 B ZA201801656 B ZA 201801656B
Authority
ZA
South Africa
Prior art keywords
methods
multiple myeloma
treating multiple
cell therapy
cell leukemia
Prior art date
Application number
ZA2018/01656A
Other languages
English (en)
Inventor
KOEHNE Guenther
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of ZA201801656B publication Critical patent/ZA201801656B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2018/01656A 2015-09-10 2018-03-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy ZA201801656B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US201562220641P 2015-09-18 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
ZA201801656B true ZA201801656B (en) 2022-12-21

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/01656A ZA201801656B (en) 2015-09-10 2018-03-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Country Status (14)

Country Link
US (1) US20190381098A1 (enExample)
EP (1) EP3347028A1 (enExample)
JP (1) JP6947720B2 (enExample)
KR (1) KR20180048992A (enExample)
CN (1) CN108348552A (enExample)
AU (1) AU2016320877A1 (enExample)
CA (1) CA2997757A1 (enExample)
HK (1) HK1257882A1 (enExample)
IL (1) IL257929B2 (enExample)
MX (1) MX395106B (enExample)
RU (1) RU2743381C2 (enExample)
TW (1) TWI759270B (enExample)
WO (1) WO2017044678A1 (enExample)
ZA (1) ZA201801656B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
AU2013207669C1 (en) * 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
JP6947720B2 (ja) 2021-10-13
JP2018530534A (ja) 2018-10-18
IL257929B2 (en) 2024-06-01
MX395106B (es) 2025-03-21
TWI759270B (zh) 2022-04-01
CN108348552A (zh) 2018-07-31
MX2018002816A (es) 2018-06-08
US20190381098A1 (en) 2019-12-19
AU2016320877A1 (en) 2018-04-19
HK1257882A1 (zh) 2019-11-01
WO2017044678A1 (en) 2017-03-16
RU2018112526A (ru) 2019-10-10
RU2018112526A3 (enExample) 2020-01-31
TW201714619A (zh) 2017-05-01
IL257929A (en) 2018-05-31
RU2743381C2 (ru) 2021-02-17
EP3347028A1 (en) 2018-07-18
KR20180048992A (ko) 2018-05-10
IL257929B1 (en) 2024-02-01
CA2997757A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
GB2607227B (en) Viral methods of T cell therapy
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
IL253795B (en) Methods for treating cancer using activated t cells
GB2557123B (en) Modified cells and methods of therapy
ZA201708567B (en) Methods of treating epithelioid cell tumors
IL259992A (en) A method for treating increased sensitivity to pain
ZA201706059B (en) Method of treatment with tradipitant
EP3319619A4 (en) Methods of treating colitis
ZA201807431B (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
IL256207B (en) Methods for treating multiple sclerosis
ZA201801656B (en) Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
SG11201706693QA (en) Methods of treating infertility
IL253847A0 (en) Methods of treating diseases
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
EP3281243A4 (en) Method of treating carbon electrode
IL267231A (en) Methods of treating diseases associated with ilc2 cells
IL262951A (en) Methods of drug therapy associated with ilc3 cells
GB201512139D0 (en) Methods of treatment
HK40035157A (en) Methods of treating high risk multiple myeloma
PT3265075T (pt) Terapêutica de associação com roneparstat para o mieloma múltiplo
HK1262625A1 (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
PT3261661T (pt) Menotropina para tratar a infertilidade
GB201512334D0 (en) Methods for selective killing of cancer cells